Premature ovarian failure and ovarian dysgenesis {#sec1-1}
================================================

Premature ovarian failure (POF) is a frequent and heterogeneous disorder (1-2% of women under age 40 years, 1:10000 women under age 20 years and 1:1000 under 30 years) due to anomalies in follicular development. It is characterized by early functional blockade of the ovary (with respect to menopause which normally occurs after age 45 years) and menstrual cycles can be completely absent (primary amenorrhea) or end before 40 years of age (secondary amenorrhea). The most severe forms are caused by ovarian dysgenesis (50% of cases of primary amenorrhea), whereas post-pubertal forms are characterized by disappearance of the menstrual cycle (secondary amenorrhea) ([@ref1]).

Biochemically, premature ovarian failure is characterized by reduced levels of gonad hormones (estrogens) and increased levels of gonadotropins (LH and FSH) ([@ref2]). Ovarian dysgenesis is characterized by absence of gonad development, gonadotropin resistance and normal development of the external and internal genitalia ([@ref3]). Chromosome anomalies (deletions, translocations) and pre-mutation status of the *FMR1* gene are frequent causes of POF (estimated prevalence 10-13%) ([@ref4]). Several studies have identified genes important for ovarian development and onset of POF ([Table 1](#T1){ref-type="table"}). Mutations in the *BMP15* gene have been identified in 1.5-15% of Caucasian, Indian and Chinese women with POF ([@ref5]). One third of patients with POF have mutations in *PGRMC1* while changes in levels of the encoded protein are known to cause POF through impaired activation of microsomal cytochrome P450 and excessive apoptosis of ovarian cells ([@ref6]). In 1-2% of cases, mutations in *GDF9*, *FIGLA*, *NR5A1* and *NANOS3* have been identified ([@ref6]). Whole exome sequencing (WES) in large families has detected mutations in genes important for homologous recombination and meiosis (*STAG3*, *SYCE1*, *HFM1*), DNA repair (*MCM8*, *MCM9*, *ERCC6*, *NUP107*), mRNA transcription (*SOHLH1*) and mRNA translation (*eIF4ENIF1*) ([@ref7]).

###### 

Genes associated with primary ovarian failure and ovarian dysgenesis

  Gene          Inheritance   OMIM gene ID   OMIM phenotype   OMIM or HGMD phenotype ID   Clinical Features
  ------------- ------------- -------------- ---------------- --------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  *HFM1*        AR            615684         POF9             615724                      Amenorrhea
  *FIGLA*       AD            608697         POF6             612310                      Small/absent ovaries, follicles absent, atrophic endometrium
  *FOXL2*       AD            605597         POF3             608996                      Hypoplastic uterus and ovaries, follicles absent, secondary amenorrhea
  *MSH5*        AR            603382         POF13            617442                      Oligomenorrhea, atrophic ovaries, follicles absent
  *STAG3*       AR            608489         POF8             615723                      Primary amenorrhea, ovarian dysgenesis
  *NOBOX*       AD            610934         POF5             611548                      Secondary amenorrhea, follicles absent
  *NR5A1*       AD            184757         POF7             612964                      Irregular or anovulatory menstrual cycles, secondary amenorrhea, dysgenetic gonads, no germ cells
  *ERCC6*       AD            609413         POF11            616946                      Secondary amenorrhea
  *SYCE1*       AR            611486         POF12            616947                      Primary amenorrhea, small prepubertal uterus and ovaries, no ovarian follicles
  *MCM8*        AR            608187         POF10            612885                      Absent thelarche, primary amenorrhea, no ovaries, hypergonadotropic ovarian failure
  *BMP15*       XLD           300247         POF4, OD2        300510                      Delayed puberty, primary/secondary amenorrhea, small ovaries, follicles absent, hypoplastic uterus, hirsutism, absent pubic/axillary hair
  *FLJ22792*    XLR           300603         POF2B            300604                      Weak teeth, delayed puberty, primary amenorrhea, osteoporosis
  *DIAPH2*      XLD           300108         POF2A            300511                      Secondary amenorrhea
  *FSHR*        AR            136435         OD1              233300                      Osteoporosis, primary amenorrhea
  *MCM9*        AR            610098         OD4              616185                      Short stature, low weight, underdeveloped breasts, no ovaries, retarded bone age and development of pubic/ axillary hair, primary amenorrhea
  *SOHLH1*      AR            610224         OD5              617690                      Short stature, absent thelarche, primary amenorrhea, hypoplastic/no ovaries, small uterus, retarded bone age
  *PSMC3IP*     AR            608665         OD3              614324                      Underdeveloped breasts and absent pubic hair, hypoplastic uterus, primary amenorrhea
  *AMH*         AD            600957         POF              782468699                   Primary/secondary amenorrhea
  *AMHR2*       AD            600956         POF              1454100025                  Primary ovarian insufficiency
  *DAZL*        AR            601486         POF              782468699                   Low ovarian reserves
  *GDF9*        AR            601918         POF14            618014                      Primary amenorrhea, no breast development, delayed pubic hair development
  *LHCGR*       AR            152790         POF              1754122511                  Primary amenorrhea
  *INHA*        AD, AR        147380         POF              782468699                   Primary amenorrhea
  *PGRMC1*      AD            300435         POF              782468699                   Hypergonadotropic hypogonadism, amenorrhea
  *POU5F1*      AD            164177         POF              782468699                   Small ovaries without follicles
  *TGFBR3*      AD            600742         POF              782468699                   Premature ovarian failure
  *WT1*         AD            607102         POF              782468699                   Secondary amenorrhea
  *SGO2*        AR            612425         POF              141105721                   Ovarian insufficiency
  *SPIDR*       AR            615384         POF              141105721                   Hypoplastic/no ovaries
  *EIF4ENIF1*   AD            607445         POF              141105721                   Secondary amenorrhea
  *NUP107*      AR            607617         OD6              618078                      No ovaries, small uterus, no spontaneous puberty
  *NANOS3*      AD            608229         POF              729748889                   Primary amenorrhea

OD=ovarian dysgenesis; POF = primary ovarian failure; HGMD = Human Gene Mutation Database (https://portal.biobase-international.com/hgmd/pro/)

MAGI uses a multi-gene next generation sequencing (NGS) panel to detect nucleotide variations in coding exons and flanking introns of the above genes.

Oocyte maturation defects and pre-implantation embryonic lethality {#sec1-2}
==================================================================

Oocyte maturation is defined as re-initiation and completion of the first meiotic division, subsequent progression to the second phase of meiosis, and other molecular events essential for fertilization and early embryo development ([@ref8]). The meiotic cell cycle begins in the neonatal ovary and stops at prophase I of meiosis until puberty, when an increase in luteinizing hormone concentrations re-initiates meiosis and ovulation. Thus the oocyte progresses from metaphase I to metaphase II. Metaphase I is completed by extrusion of a polar body. Mature oocytes are again arrested at metaphase II, the only stage at which they can be successfully fertilized ([@ref9]).

Microscope observation of mature oocytes shows a single polar body, a homogeneous cytoplasm, a *zona pellucida* (ZP) and a perivitelline space. The *zona pellucida* is an extracellular matrix surrounding the oocytes of mammals and is fundamental for oogenesis, fertilization and pre-implantation embryo development. It consists of four glycoproteins (ZP1-ZP4) and ensures species-specific fertilization and induction of the sperm acrosomal reaction during fertilization. It also contains sperm receptors, contributes to blocking polyspermy and protects early embryos until implantation. Glycoprotein ZP1 connects ZP2 with ZP3. ZP2 is a structural component of the *zona pellucida* and has a role in sperm binding and penetration after the acrosomal reaction. ZP3 is a receptor that binds sperm at the beginning of fertilization and induces the acrosomal reaction ([@ref10]). Oocyte maturation can be arrested in various phases of the cell cycle. Until recently, the genetic events underlying oocyte maturation arrest were unknown ([@ref9]). Only in the last few years have pathogenic genetic variations that cause oocyte maturation defects been found. In particular, heterozygous mutations in the tubulin beta 8 gene (*TUBB8*) cause defects in the assembly of the meiotic spindle and in oocyte maturation ([@ref11]). Pathogenic variations in *TUBB8* can be found in \~30% of cases with oocyte maturation arrest; mutations in *PATL2* and genes that encode ZP proteins are less frequent ([@ref12]).

Early arrest of embryo development is one of the main causes of female infertility, although diagnosis can be difficult and the genetic causes are largely unknown. Gene-disease is difficult to identify, but studies on animal models suggest that there may be hundreds. A recent study identified a homozygous mutation in *TLE6* in a case of pre-implantation embryonic lethality with reduced female fertility and embryo development arrest at the meiosis II phase of the oocyte ([@ref13]). Another study found that mutations in *PADI6* cause early embryonic arrest due to lack of activation of the zygotic genome ([@ref14]). PADI6 may be involved in formation of the subcortical maternal complex, essential for the embryo to go through the two-cell stage in mice as well as humans.

The current list of genes associated with oocyte maturation defects and pre-implantation embryonic lethality includes *ZP1*, *TUBB8*, *ZP3*, *PATL2*, *ZP2*, *TLE6* and *PADI6* ([Table 2](#T2){ref-type="table"}).

###### 

Genes associated with oocyte maturation defect and preimplantation embryonic lethality

  Gene      Inheritance   OMIM gene ID   OMIM phenotype   OMIM phenotype ID   Clinical Features
  --------- ------------- -------------- ---------------- ------------------- --------------------------------------------------------------------------------------------------------------------------------------
  *ZP3*     AD            182889         OOMD3            617712              Oocyte degeneration, absence of zona pellucida
  *TUBB8*   AD, AR        616768         OOMD2            616780              Oocyte arrest at metaphase I or II; abnormal spindle
  *ZP1*     AR            195000         OOMD1            615774              Absence of zona pellucida
  *PATL2*   AR            614661         OOMD4            617743              Oocyte maturation arrest in germinal vesicle stage, metaphase I or polar body 1 stage; abnormal polar body 1; early embryonic arrest
  *ZP2*     AR            182888         OOMD6            618353              Abnormal of zona pellucida
  *TLE6*    AR            612399         PREMBL1          616814              Failure of zygote formation
  *PADI6*   AR            610363         PREMBL2          617234              Recurrent early embryonic arrest

OOMD=oocyte maturation defect; PREMBL=preimplantation embryonic lethality.

MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes.

Sporadic and recurrent pregnancy loss {#sec1-3}
=====================================

Recurrent pregnancy loss is defined as two or more consecutive miscarriages before the 20^th^ week of gestation ([@ref15]) and affects 1-5% of women of fertile age. Several other conditions have been associated with recurrent pregnancy loss: chromosome anomalies in parents or embryo, prothrombotic states, structural anomalies of the uterus, endocrine dysfunction, infections and immunological factors. Although there has been progress in the clinical and biochemical diagnosis of the human infertility, it is estimated that 35-60% of cases are still considered idiopathic, suggesting that genetic, epigenetic and environmental factors contribute to the recurrent pregnancy loss phenotype ([@ref16]).

Fetal aneuploidies are the most frequent cause of sporadic miscarriage and can be detected in 50-70% of miscarriages in the first trimester and 5-10% of all pregnancies. The most frequent chromosome aberrations are trisomy, triploidy and X monosomy. Chromosome anomalies can also be found in the parental karyotype in 4-6% of couples with at least two miscarriages, and are more frequent in women. The most common anomaly found in couples is unbalanced translocation. Carriers are phenotypically healthy, but about 50-60% of their gametes are unbalanced due to anomalous meiotic segregation ([@ref17]).

Single genes or few genes as the main cause of recurrent pregnancy loss have been less considered. However, in couples with recurrent pregnancy loss, identification of mutations in the *SYCP3* gene, which encodes a fundamental component of the synaptonemal complex involved in meiotic segregation, has demonstrated a correlation between meiosis, aneuploidy and recurrent miscarriages. This suggests that correct segregation of chromosomes is influenced by events that take place in the fertilization phase, during meiosis I ([@ref18],[@ref19]).

Recurrent miscarriage can also be linked to thrombophilia. In fact, mutations in the Leiden factor V gene (*F5*), coagulation factor II gene (*F2*) and annexin A5 gene (*ANXA5* encoding an anticoagulant protein active in placental villi), have been associated with increased risk of recurrent pregnancy loss. Finally, mutations in *NLRP7* and *KHDC3L* have been associated with hydatidiform mole, a disease of the trophoblast. Hydatidiform mole is due to a fertilization defect and is characterized by trophoblast proliferation that prevents normal embryo development. Mutations in the two genes have been reported in 1% of cases of hydatidiform mole.

The current list of genes known to be associated with recurrent pregnancy loss is reported in [Table 3](#T3){ref-type="table"}.

###### 

Genes associated with recurrent pregnancy loss.

  Gene     Inheritance   OMIM gene ID   OMIM phenotype   OMIM phenotype ID   Clinical Features
  -------- ------------- -------------- ---------------- ------------------- ------------------------------------------
  SYCP3    AD            604759         RPRGL4           270960              Fetal loss after 6-10 weeks of gestation
  F2       AD            176930         RPRGL2           614390              Recurrent miscarriage
  ANXA5    AD            131230         RPRGL3           614391              
  NLRP7    AR            609661         HYDM1            231090              Gestational trophoblastic disease
  KHDC3L   AR            611687         HYDM2            614293              

RPRGL=recurrent pregnancy loss; PREMBL=preimplantation embryonic lethality.

MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes.

Ovarian hyperstimulation syndrome {#sec1-4}
=================================

Ovarian hyperstimulation syndrome (OHSS, OMIM phenotype: 608115) is a potentially life-threatening condition. It is a systemic disorder caused by excessive secretion of vasoactive hormones by hyperstimulated ovaries. The physiopathology is characterized by an increase in capillary permeability with leakage into the vasal compartment and intravascular dehydration. Severe complications include thrombophilia, renal and hepatic dysfunction and acute respiratory distress ([@ref20]).

The syndrome is defined as having early onset when it manifests in luteal phase in response to human chorionic gonadotropin (hCG). It is defined as having late onset when it manifests at the beginning of pregnancy and endogenous hCG further stimulates the ovary. It is often induced by ovarian stimulation used for *in vitro* fertilization, although 0.5-5% of cases are spontaneous. Clinical manifestations may range from benign abdominal distension to massive, potentially lethal ovarian enlargement ([@ref21]). Pathological features of the syndrome, both spontaneous and iatrogenic, include multiple serous and hemorrhagic follicular cysts surrounded by luteal cells (*iperreactio luteinalis*). The syndrome can arise from high serous levels of hCG caused by multiple or molar pregnancies. It can also be associated with pituitary or neuroendocrine adenomas stimulating follicular hormone (FSH), with hypothyroidism, or with activating mutations of the FSH receptor (FSHR) ([@ref22]).

Five activating mutations in the *FSHR* gene have been described in pregnant women with OHSS. These mutations increase sensitivity to hCG and/or thyroid stimulating hormone (TSH). By contrast, loss-of-function mutations in *FSHR* can severely upset folliculogenesis, causing ovarian insufficiency. Recent studies reported cases with non-gestational OHSS with new mutations in *FSHR* ([@ref23]-[@ref26]).

To date, the only gene known to be associated with OHSS is *FSHR* (OMIM gene ID: 136435) and the phenotype has autosomal dominant inheritance.

MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of *FSHR*.

Conclusions {#sec1-5}
===========

Infertility is a significant and increasing clinical problem. Several chromosome aberrations have long been known to be associated with female infertility. Only recently have monogenic mutations been found in association with male and female infertility. Genetic tests based on parallel sequencing of several genes are becoming increasingly important in diagnostic practice.

We created a NGS panel to detect nucleotide variations in coding exons and flanking regions of all the genes associated with infertility. When a suspect of female infertility is present we perform the analysis of all the genes present in this short article. In order to have a high diagnostic yield, we developed a NGS test that reaches an analytical sensitivity (proportion of true positives) and an analytical specificity (proportion of true negatives) of ≥99% (coverage depth ≥10x).

Knowledge of the exact molecular cause helps clinicians choose the most appropriate treatments and follow-up.
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